News
Wed, 05 Feb 2025 06:00:00 -0500
Wed, 05 Feb 2025 06:00:00 -0500
Financial report for the period 1 January 2024 to 31 December 2024
|
PROFIT AND LOSS |
2024 |
2023 |
Growth as reported |
Growth at CER* |
|
USD million |
|
|
|
|
|
Net sales |
42,121 |
33,711 |
25% |
26% |
|
Operating profit |
18,615 |
14,888 |
25% |
26% |
|
|
|
|
|
|
|
Net profit |
14,648 |
12,146 |
21% |
N/A |
|
Diluted earnings per share (in USD) |
3.28 |
2.70 |
22% |
N/A |
|
* CER: Constant exchange rates (average 2023). ** For convenience, Danish Kroner has been translated to USD in this release, using the average exchange rates of USD 1.0 = DKK 6.89448 and the period-end exchange rate of USD 1.0 = DKK 7.14286 |
||||
Lars Fruergaard Jørgensen, president and CEO: "We are pleased with the performance in 2024, where 26% sales growth reflects that more than 45 million people are now benefiting from our treatments. Further, we completed the acquisition of the three Catalent sites, and during the year, we progressed our R&D pipeline, including obesity projects such as CagriSema and amycretin. In 2025, we will continue our focus on commercial execution, on the progression of our early and late-stage R&D pipeline and on the expansion of our production capacity."
On 5 February 2025 at 13.00 CET, corresponding to 07.00 am EST, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under 'Investors' (the contents of the company's website do not form a part of this Form 6-K).